Severe cases of uveitis, such as intermediate uveitis, panuveitis, Vogt–Koyanagi–Harada-like syndrome, ischemic retinal vasculitis, and multifocal choroiditis complicated by choroidal neovascularization, have been reported, and these required the discontinuation of BRAF inhibitor therapy, along with specific ocular treatments [65,66,67,68]. Here, BRAF is linked to intermediate uveitis.